- Conditions
- Major Depressive Disorder, Depression
- Interventions
- venlafaxine XR, buprenorphine, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder, Treatment Resistant Depression
- Interventions
- Aripiprazole Augmentation, Bupropion Augmentation
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Pittsburgh, Pennsylvania
- Conditions
- Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression, Geriatric Depression
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
- Interventions
- L-Dopa, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Depression
- Interventions
- Buprenorphine
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Treatment Resistant Depressive Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 55 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
- Interventions
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
- Drug
- Lead sponsor
- Centre for Addiction and Mental Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York
- Conditions
- Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Eric Lenze
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • St Louis, Missouri
- Conditions
- Depression
- Interventions
- venlafaxine XR plus aripiprazole, venlafaxine plus placebo
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Pittsburgh, Pennsylvania
- Conditions
- Depression, Dementia, Mild Cognitive Impairment
- Interventions
- Mechanisms of Late life depression (LLD)-dementia through functional Magnetic Resonance Imaging (fMRI), Neuropsychological Data, Clinical Scales
- Behavioral
- Lead sponsor
- Centre for Addiction and Mental Health
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
- Interventions
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • St Louis, Missouri • New York, New York + 1 more